Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Heterocyclic carbon compounds containing a hetero ring...
Reexamination Certificate
2007-07-17
2007-07-17
Tucker, Zachary C. (Department: 1624)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Heterocyclic carbon compounds containing a hetero ring...
C514S249000, C514S252110, C540S575000, C540S598000, C544S354000, C544S357000
Reexamination Certificate
active
10622055
ABSTRACT:
Compounds of the general formula (I):wherein m, n, R1, R2, R3and R4are as described in the specification.Further included are pharmaceutical compositions comprising the compounds, processes for their preparation, as well as the use of the compounds for the preparation of a medicament for the treatment of 5-HT2Areceptor-related disorders or medical conditions.
REFERENCES:
patent: 4163849 (1979-08-01), Lumma, Jr. et al.
patent: 5134149 (1992-07-01), Carr et al.
patent: 5538974 (1996-07-01), Ogawa et al.
patent: 6143792 (2000-11-01), Cattelin
patent: 6358977 (2002-03-01), Carlsson
patent: 0522226 (1991-12-01), None
patent: 0695545 (1995-06-01), None
patent: 1440722 (1976-06-01), None
patent: 1492528 (1977-11-01), None
patent: WO 95/33721 (1995-12-01), None
patent: WO 00/12090 (2000-03-01), None
patent: WO 00/76984 (2000-12-01), None
patent: WO 01/89498 (2001-11-01), None
de Angelis, “5-HT2A antagonists in psychiatric disorders” Current Opinion in Investigational Drugs, vol. 3(1), pp. 106-112 (2002).
Kihara et al, “AT-1015, a Novel Serotonin (5-HT)2 Receptor Antagonist, Blocks Vascular and Platelet 5-HT2A Receptors and Prevents the Laurate-Induced Peripheral Vascular Lesion in Rats” Journal of Cardiovascular Pharmacology, vol. 35(4), pp. 523-530 (2000).
Hans Bundgaard, Design of Prodrugs, p. 1. © 1985 Elsevier Science Publishers.
Richard B. Silverman, The Organic Chemistry of Drug Design and Drug Action, pp. 352-400. © 1992 Academic Press, Inc.
Al-Dabbagh and Smith, “Species differences in oxidative drug metabolism: some basic considerations.” Archives of toxicology. Supplement. Archiv fur Toxikologie. supplement, vol. 7, pp. 219-231 (1984).
Camras et al, “Efficacy and Adverse Effects of Medications Used in the Treatment of Glaucoma” Drugs & Aging, vol. 15(5), pp. 377-388 (Nov. 1999).
Phelan Peter “Reappraising First-Line Treatment in Glaucoma Management” Hospital Medicine, vol. 63(9), pp. 540-545 (Sep. 2002).
Webster's II New Riverside University Dictionary, p. 944 © 1994 Houghton Mifflin Company.
Nilsson et al, “A behavioural pattern analysis of hypoglutamatergic mice—effects of four different antipsychotic agents” Journal of Neural Transmission, vol. 108, pp. 1181-1196 (2001).
Manabu Hori et al., “Design and Syntheses of a Series of Novel Serotonin3Antagonists”,Chemical&Pharmaceutical Bulletin, vol. 41, No. 10, pp. 1832-1841 (1993).
William C. Lumma, Jr., et al., “Piperazinylpyrazines with Central Serotoninmimetic Activity”,Journal of Medicinal Chemistry, vol. 21, No. 6, pp. 536-542 (1978).
William C. Lumma, Jr., et al., “Piperazinylquinoxalines with Central Serotoninmimetic Activity”,Journal of Medicinal Chemistry, vol. 24, No. 1, pp. 93-101 (1981).
Abbot, F.V., et al., “Activation of 5-HT2AReceptors Potentiates Pain Produced by Inflammatory Mediators”,Neuropharmacology, vol. 35(1), pp. 99-110, 1996.
Apelqvist, J., et al., “Ketanserin in the treatment of diabetic foot ulcer with severe peripheral vascular disease”,International Angiology, vol. 9, pp. 120-124, 1990.
Bush, L.R., et al., “The Role of the Endothelium in Arterial Thrombosis and the Influence of Antithrombotic Therapy”,Drug Development Research, vol. 7, pp. 319-340, 1986.
Cohen, M.L., “Canine, but not rat bladder contracts to serotonin via activation of 5HT2receptors”,The Journal of Urology, vol. 143, pp. 1037-1040, 1990.
Costagliola, C., et al., “Effect of tropical ketanserin administration on intraocular pressure”,British Journal of Ophthalmology, vol. 77, pp. 344-348, 1993.
Danton, G., et al., “Endothelium-targeted pharmacotherapeutics for the treatment of stroke”,Current Opinion in Investigational Drugs, vol. 3(6), pp. 896-904, 2002.
Dietrich, W.D., et al., “Effect of the serotonin antagonist ketanserin on the hemodynamic and morphological consequences of thrombotic infarction”,Journal of Cerebral Blood Flow and Metabolism, vol. 9, pp. 812-820, 1989.
Dursun, S.M., et al., “An exploratory approach to the serotonergic hypothesis of depression: bridging the synaptic gap”,Medical Hypotheses, vol. 56(2), pp. 235-243, 2001.
Furukawa, K., et al., “Therapeutic effects of sarpogrelate hydrochloride (MCI-9042) on chronic arterial occlusive diseases: a double-blind comparison with ticlopidine hydrochloride”,J. Clin. Ther. Med.1991, 7, 1747-1770.
Gelders, Y.G., “Thymosthenic agents, a novel approach in the treatment of schizophrenia”,British Journal of Psychiatry, vol. 155(suppl.), pp. 33-36, 1989.
Hara, N., et al., “Antithrombotic effect of MCI-9042, a new antiplatelet agent on experimental thrombosis models”,Thrombosis and Haemostasis, vol. 66(4), pp. 484-488, 1991.
Hemmeter, U., et al., “Schlafstorungen bei chronischen schmerzen und generalisierter tendomyopathie”,Schweiz Med Wochenschr, vol. 125, pp. 2391-2397, 1995. (Abstract Only).
Hotta, N., et al., “Effects of the 5-HT2Areceptor antagonist sarpogrelate in diabetic patients with complications”,Clin Drug Invest, vol. 18(3), pp. 199-207, 1999.
Ichiyanagi, N., et al., “Changed responsiveness of the detrusor in rabbits with alloxan induced hyperglycemia: Possible role of 5-hydroxytryptamine for diabetic bladder dysfunction”,The Journal of Urology, vol. 168, pp. 303-307, 2002.
Ishimura, E., et al., “Therapeutic effect of sarpogrelate, a new 5-hydroxytryptamine receptor 2A antagonist, on diabetic nephropathy and neuropathy”,Nephron, vol. 76, pp. 227-229, 1997.
Jackson, J., et al., “Enhancement of [m-methoxy 3H]MDL100907 binding to 5HT2Areceptors in cerebral cortex and brain stem of streptozotocin induced diabetic rats”,Molecular and Cellular Biochemistry, vol. 199, pp. 81-85, 1999.
Kaplan, S.A., et al., “Urodynamic findings in patients with diabetic cystopathy”,The Journal of Urology, vol. 153, pp. 342-344, 1995.
Kihara, H., et al., “Antithrombotic activity of AT-1015, a potent 5-HT2Areceptor antagonist, in rat arterial thrombosis model and its effect on bleeding time”,European Journal of Pharmacology, vol. 433, pp. 157-162, 2001.
Kim, H.J., et al., “Acute effects of serotonin on rat bladder contractility”,Urologia Internationalis, vol. 68, pp. 44-48, 2002.
Kobori, S., et al., “Effect of 5-hydroxytryptamine2Areceptor antagonist on the development of diabetic nephropathy in early stage”,Diabetes Mellitus: Recent Advances for the 21stCentury, pp. 283-286, 2000.
Kodama, M., et al., “Influence of 5-hydroxytrytamine and the effect of a new serotonin receptor antagonist (sarpogrelate) on detrusor smooth muscle of streptozotocin-induced diabetes mellitus in the rat”,International Journal of Urology, vol. 7, pp. 231-235, 2000.
Leysen, D., et al., “5-HT2antagonists: a concept for the treatment of schizophrenia”,Current Pharmaceutical Design, vol. 3, pp. 367-390, 1997.
Malyszko, J., et al., “Daily variations of platelet aggregation in relation to blood and plasma serotonin in diabetes”,Thrombosis Research, vol. 75(5), pp. 569-576, 1994.
Mano, T., et al., “The effect of anplag (sarpogrelate HCI), new selective 5-HT2antagonist on intraocular pressure in rabbits”,Investigative Ophthalmology&Visual Science, vol. 36(4), pp. 3322-3309, 1995.
Martinzez-De Jesus, F.R., et al., “Randomized single-blind trial of topical ketanserin for healing acceleration of diabetic foot ulcers”,Archives of Medical Research, vol. 28(1), pp. 95-99, 1997.
Menendez, V., et al., “Urodynamic evaluation in simultaneous insulin-dependent diabetes mellitus and end stage renal disease”,The Journal of Urology, vol. 155, pp. 2001-2004, 1996.
Mermoud, A., et al., “Le traitment du glaucoma a pression normale avec un antagoniste des recepteurs S2 del la serotonine, le naftidrofuryl (praxilen)
Cernerud Magnus
Lundström Helena
Nilsson Björn M
Thor Markus
Biovitrum AB
Fish & Richardson P.C.
Tucker Zachary C.
LandOfFree
Amino-substituted 1H-pyrazin-2-ones and 1H-quinoxalin-2-ones does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Amino-substituted 1H-pyrazin-2-ones and 1H-quinoxalin-2-ones, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Amino-substituted 1H-pyrazin-2-ones and 1H-quinoxalin-2-ones will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3803247